Randomized, Double-blind, Placebo- and Active Comparator- Controlled Crossover Study in Healthy Male Subjects and an Open Label Study in Healthy Subjects and MS Patients to Assess the Safety, Pharmacokinetics and Pharmacodynamics of 2B3-201

Trial Profile

Randomized, Double-blind, Placebo- and Active Comparator- Controlled Crossover Study in Healthy Male Subjects and an Open Label Study in Healthy Subjects and MS Patients to Assess the Safety, Pharmacokinetics and Pharmacodynamics of 2B3-201

Discontinued
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2015

At a glance

  • Drugs Methylprednisolone (Primary) ; Methylprednisolone sodium succinate
  • Indications Multiple sclerosis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors BBB Therapeutics
  • Most Recent Events

    • 05 Feb 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 12 Jan 2015 Planned End Date changed from 1 Jan 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.
    • 12 Jan 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top